Chapter 15. Matrix metalloproteinase inhibitors for treatment of cancer
- 1 January 2000
- book chapter
- Published by Elsevier
Abstract
No abstract availableThis publication has 34 references indexed in Scilit:
- Asymmetric Synthesis of Mercaptoalcohols - Matrix Metalloproteinase InhibitorsSynlett, 1999
- P1, P2′-Linked macrocyclic amine derivatives as matrix metalloproteinase inhibitorsBioorganic & Medicinal Chemistry Letters, 1999
- Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-α productionBioorganic & Medicinal Chemistry Letters, 1999
- Innate Immunity: The Bridge between Adaptive Immunity and Inflammation, December 17, 1998, New York Academy of Sciences, New York, NY, USAInflammation Research, 1999
- Discovery of a novel series of selective MMP inhibitors: Identification of the γ-sulfone-thiolsBioorganic & Medicinal Chemistry Letters, 1999
- Cloning and Characterization of Human MMP-23, a New Matrix Metalloproteinase Predominantly Expressed in Reproductive Tissues and Lacking Conserved Domains in Other Family MembersJournal of Biological Chemistry, 1999
- Anti-angiogenic therapies in cancer clinical trialsExpert Opinion on Investigational Drugs, 1998
- Solution Structure of the Catalytic Domain of Human Stromelysin-1 Complexed to a Potent, Nonpeptidic InhibitorBiochemistry, 1998
- Design and synthesis of the cartilage protective agent (CPA, Ro32-3555)Bioorganic & Medicinal Chemistry Letters, 1997
- Matrix Metalloproteinase Inhibitor DrugsEmerging Drugs, 1997